BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28442586)

  • 1. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
    Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
    Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy for atypical teratoid rhabdoid tumors: case report.
    Thatikunta M; Mutchnick I; Elster J; Thompson MP; Huang MA; Spalding AC; Moriarty T
    J Neurosurg Pediatr; 2017 May; 19(5):546-552. PubMed ID: 28291373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
    Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
    Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities.
    Paassen I; Williams J; Ríos Arceo C; Ringnalda F; Mercer KS; Buhl JL; Moreno N; Federico A; Franke NE; Kranendonk M; Upadhyaya SA; Kerl K; van de Wetering M; Clevers H; Kool M; Hoving EW; Roussel MF; Drost J
    Oncogene; 2023 May; 42(20):1661-1671. PubMed ID: 37020038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
    Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
    Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
    Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
    Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
    Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup.
    Johann PD; Bens S; Oyen F; Wagener R; Giannini C; Perry A; Raisanen JM; Reis GF; Nobusawa S; Arita K; Felsberg J; Reifenberger G; Agaimy A; Buslei R; Capper D; Pfister SM; Schneppenheim R; Siebert R; Frühwald MC; Paulus W; Kool M; Hasselblatt M
    Am J Surg Pathol; 2018 Apr; 42(4):506-511. PubMed ID: 29324471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
    Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
    Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
    J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort.
    Benesch M; Nemes K; Neumayer P; Hasselblatt M; Timmermann B; Bison B; Ebetsberger-Dachs G; Bourdeaut F; Dufour C; Biassoni V; Morales La Madrid A; Entz-Werle N; Laithier V; Quehenberger F; Weis S; Sumerauer D; Siebert R; Bens S; Schneppenheim R; Kool M; Modena P; Fouyssac F; C Frühwald M
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28022. PubMed ID: 31571386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.
    Johann PD; Hovestadt V; Thomas C; Jeibmann A; Heß K; Bens S; Oyen F; Hawkins C; Pierson CR; Aldape K; Kim SP; Widing E; Sumerauer D; Hauser P; van Landeghem F; Ryzhova M; Korshunov A; Capper D; Jones DTW; Pfister SM; Schneppenheim R; Siebert R; Paulus W; Frühwald MC; Kool M; Hasselblatt M
    Brain Pathol; 2017 Jul; 27(4):411-418. PubMed ID: 27380723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
    Roehrig A; Indelicato DJ; Paulino AC; Ermoian R; Hartsell W; Perentesis J; Hill-Kayser C; Lee JY; Laack NN; Mangona V; MacEwan I; Eaton BR; Gallotto S; Bajaj BVM; Aridgides PD; Yock TI
    J Neurooncol; 2023 Apr; 162(2):353-362. PubMed ID: 36951945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.
    Johann PD; Erkek S; Zapatka M; Kerl K; Buchhalter I; Hovestadt V; Jones DTW; Sturm D; Hermann C; Segura Wang M; Korshunov A; Rhyzova M; Gröbner S; Brabetz S; Chavez L; Bens S; Gröschel S; Kratochwil F; Wittmann A; Sieber L; Geörg C; Wolf S; Beck K; Oyen F; Capper D; van Sluis P; Volckmann R; Koster J; Versteeg R; von Deimling A; Milde T; Witt O; Kulozik AE; Ebinger M; Shalaby T; Grotzer M; Sumerauer D; Zamecnik J; Mora J; Jabado N; Taylor MD; Huang A; Aronica E; Bertoni A; Radlwimmer B; Pietsch T; Schüller U; Schneppenheim R; Northcott PA; Korbel JO; Siebert R; Frühwald MC; Lichter P; Eils R; Gajjar A; Hasselblatt M; Pfister SM; Kool M
    Cancer Cell; 2016 Mar; 29(3):379-393. PubMed ID: 26923874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics.
    Nesvick CL; Lafay-Cousin L; Raghunathan A; Bouffet E; Huang AA; Daniels DJ
    J Neurooncol; 2020 Oct; 150(1):47-56. PubMed ID: 33021733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
    Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
    Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
    Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
    J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical teratoid/rhabdoid tumors.
    Dang T; Vassilyadi M; Michaud J; Jimenez C; Ventureyra EC
    Childs Nerv Syst; 2003 Apr; 19(4):244-8. PubMed ID: 12682757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.
    Frühwald MC; Hasselblatt M; Nemes K; Bens S; Steinbügl M; Johann PD; Kerl K; Hauser P; Quiroga E; Solano-Paez P; Biassoni V; Gil-da-Costa MJ; Perek-Polnik M; van de Wetering M; Sumerauer D; Pears J; Stabell N; Holm S; Hengartner H; Gerber NU; Grotzer M; Boos J; Ebinger M; Tippelt S; Paulus W; Furtwängler R; Hernáiz-Driever P; Reinhard H; Rutkowski S; Schlegel PG; Schmid I; Kortmann RD; Timmermann B; Warmuth-Metz M; Kordes U; Gerss J; Nysom K; Schneppenheim R; Siebert R; Kool M; Graf N
    Neuro Oncol; 2020 Jul; 22(7):1006-1017. PubMed ID: 31883020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.